Moderna withholds 1.63 mln COVID-19 vaccine doses in Japan due to contamination


Aug 25 (Reuters) – Moderna Inc (MRNA.O) has withheld supply of about 1.63 million doses in Japan after it was notified of contamination of its COVID-19 vaccine vials with particulate matter, the U.S. vaccine maker said on Wednesday.

The contamination, the company said, could be due to a manufacturing issue in one of the production lines at its contract manufacturing site in Spain.

The lot with complaints had 565,400 doses and “out of an abundance of caution” Moderna has put on hold the lot and two adjacent ones.

“To date, no safety or efficacy issues have been identified,” Moderna said, adding that it would work with its partner Takeda Pharmaceutical (4502.T) as well as the regulators to address the issue.

Takeda said it conducted an emergency examination after particulate matter was found in a lot of vaccine vials at an inoculation site.

The health ministry said on early Thursday it decided to withdraw some doses as a precaution after consultation with Takeda but will strive to minimize the impact of the withdrawal on its inoculation plans.

Prime Minister Yoshihide Suga had said on Wednesday about 60% of the public will be fully vaccinated by September end and that the country had enough vaccines to provide booster doses if such a decision is taken. read more

Nikkei first reported the news about the contaminated vials, citing the health ministry.

Reporting by Manojna Maddipatla and Nikhil Kurian Nainan in Bengaluru; Editing by Arun Koyyur

Our Standards: The Thomson Reuters Trust Principles.



Read More:Moderna withholds 1.63 mln COVID-19 vaccine doses in Japan due to contamination

2021-08-25 23:54:00

Get real time updates directly on you device, subscribe now.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.